|
|
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Number of employees : 1 167 people.
|
|
|
| 2020 | 2021 | Delta | | Tumor Treating Fields | 494.37 | 100% | 535.03 | 100% | +8.23% |
| USD in Million |
|
|
|
| 2020 | 2021 | Delta | | United States | 340.78 | 68.9% | 353.11 | 66% | +3.62% |
| Germany | 93.26 | 18.9% | 93.94 | 17.6% | +0.72% |
| Japan | 29.08 | 5.9% | 34.64 | 6.5% | +19.14% |
| Other EMEA | 18.65 | 3.8% | 30.58 | 5.7% | +63.92% |
| Greater China | 12.59 | 2.5% | 22.77 | 4.3% | +80.82% |
| USD in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
104,586,094 |
90,487,581 |
86.5% |
0 |
0.0% |
86.5% |
|
|
|
| Name | Equities | % | | Capital Research & Management Co. (World Investors) | 12,650,643 |
12.1% | | Capital Research & Management Co. (International Investors) | 11,345,026 |
10.8% | | Capital Research & Management Co. (Global Investors) | 11,082,364 |
10.6% | | Baillie Gifford & Co. | 9,340,845 |
8.93% | | Hansjörg Wyss | 8,141,397 |
7.78% | | The Vanguard Group, Inc. | 7,799,564 |
7.46% | | Fidelity Management & Research Co. LLC | 6,285,056 |
6.01% | | Gert Lennart Perlhagen | 4,501,700 |
4.30% | | SSgA Funds Management, Inc. | 2,498,569 |
2.39% | | T. Rowe Price Associates, Inc. (Investment Management) | 2,113,151 |
2.02% |
|
| Company contact information |
|
NovoCure Ltd. No. 4 The Forum Grenville Street 2nd Floor St. Helier, Jersey JE2 4UF Phone : +44.15.3475.6700 Web : http://www.novocure.com |
|
|
| | 1st jan. | Capi. (M$) |
 | NOVOCURE LIMITED | 0.69% | 7 907 |
| | | |
| MASIMO CORPORATION | -52.66% | 7 693 |
| SHOCKWAVE MEDICAL, INC. | 10.86% | 7 076 |
 | GETINGE AB | -41.69% | 6 197 |
| PENUMBRA, INC. | -54.15% | 4 964 |
 | IRAY TECHNOLOGY COMPANY LIMITED | -5.78% | 4 891 |
| JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. | -29.31% | 3 946 |
 | ASAHI INTECC CO., LTD. | -20.68% | 3 941 |
| INARI MEDICAL, INC. | -22.06% | 3 779 |
| TOFFLON SCIENCE AND TECHNOLOGY GROUP CO., LTD. | -35.73% | 3 012 |
| SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD. | -22.39% | 2 867 |
| APT MEDICAL INC. | -20.71% | 2 193 |
| SHENZHEN YHLO BIOTECH CO., LTD. | -15.43% | 1 750 |
| IMPLANTICA AG | -27.92% | 1 310 |
| TREACE MEDICAL CONCEPTS, INC. | -18.13% | 844 |
| SHANGHAI SANYOU MEDICAL CO., LTD. | -22.46% | 704 |
| PULMONX CORPORATION | -50.58% | 588 |
 | MICROTECH MEDICAL (HANGZHOU) CO., LTD. | -60.63% | 526 |
| BIOVENTUS INC. | -43.75% | 500 |
| SI-BONE, INC. | -35.66% | 485 |
| IRADIMED CORPORATION | -30.73% | 402 |
Connections : NovoCure Limited |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
